Windtree Therapeutics, Inc.
2600 Kelly Road, Suite 100
Warrington, Pennsylvania 18976
April 24, 2024
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, NE
Washington, D.C. 20549
|
Re: |
Windtree Therapeutics, Inc. |
| Registration Statement on Form S-1 | |
| SEC File No. 333-284976 | |
| Request for Acceleration |
To whom it may concern:
Pursuant to Rule 461 of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended, Windtree Therapeutics, Inc. (the “Company”) hereby requests that the effective date of the Company’s Registration Statement on Form S-1 (File No. 333-284976) (the “Registration Statement”) be accelerated so that the Company’s Registration Statement will become effective at 9:00 A.M., eastern time, on April 25, 2025, or as soon thereafter as is practicable, or at such other time thereafter as our counsel, Thompson Hine LLP, may request by telephone. Once the Registration Statement has been declared effective, please orally confirm that event with our counsel, Thompson Hine LLP, by calling Faith L. Charles at (212) 908-3905.
Please feel free to direct any questions or comments concerning this request to Faith L. Charles of Thompson Hine LLP at (212) 908-3905.
|
WINDTREE THERAPEUTICS, INC. |
|
|
By: |
/s/ Jed Latkin |
|
Name: Jed Latkin |
|
|
Title: President and Chief Executive Officer |
|
Cc: Faith L. Charles, Thompson Hine LLP